aminocaproic acid has been researched along with Blood Loss, Surgical in 146 studies
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.
Blood Loss, Surgical: Loss of blood during a surgical procedure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a secondary analysis of the MAssive Transfusion in Children (MATIC), a prospectively collected database of children with life-threatening hemorrhage (LTH), and evaluated for risk of adverse events with either antifibrinolytic treatment, epsilon aminocaproic acid (EACA) or tranexamic acid (TXA)." | 8.31 | Epsilon aminocaproic acid is associated with acute kidney injury after life-threatening hemorrhage in children. ( Josephson, CD; Kolodziej, JH; Leeper, CM; Leonard, JC; Spinella, PC; Zenati, MS, 2023) |
| "A prospective study evaluating the efficacy of epsilon-aminocaproic acid (EACA) in decreasing perioperative blood loss in idiopathic scoliosis." | 7.71 | The Effect of epsilon-aminocaproic acid on perioperative blood loss in patients with idiopathic scoliosis undergoing posterior spinal fusion: a preliminary prospective study. ( Adler, P; Blakemore, LC; Florentino-Pineda, I; Poe-Kochert, C; Thompson, GH; Tripi, P, 2001) |
| "The purpose of this study was to determine if a higher dosing of ε-aminocaproic acid (EACA) is associated with less perioperative blood loss than a lower dose." | 5.51 | Unexpected higher blood loss associated with higher dose ε-aminocaproic acid in pediatric scoliosis surgery. ( Austin, T; Lam, H; Martus, J; Nguyen, T; Schoenecker, J, 2019) |
| "Postoperative seizures occurred significantly more frequently in TXA patients (7." | 5.37 | Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid. ( Breuer, T; Gertler, R; Knorr, J; Lange, R; Macguill, M; Martin, K; Tassani, P; Wiesner, G, 2011) |
| "This is a prospective, randomized, double-blind comparison of tranexamic acid, epsilon-aminocaproic acid, and placebo used intraoperatively in patients with adolescent idiopathic scoliosis." | 5.19 | The relative efficacy of antifibrinolytics in adolescent idiopathic scoliosis: a prospective randomized trial. ( Boenigk, K; Diefenbach, C; Dryer, J; Errico, T; Hoelscher, C; Huncke, T; Lonner, BS; Peters, A; Verma, K, 2014) |
| "A prospective, randomized, double-blind Institutional Review Board-approved study evaluating the efficacy of Amicar (epsilon aminocaproic acid), an antifibrinolytic agent, in decreasing perioperative blood loss in idiopathic scoliosis." | 5.11 | The effect of amicar on perioperative blood loss in idiopathic scoliosis: the results of a prospective, randomized double-blind study. ( Blakemore, LC; Florentino-Pineda, I; Haber, LL; Huang, RP; Poe-Kochert, C; Thompson, GH, 2004) |
| " The aim of this study was to review the literature on the use of lysine analogs to prevent bleeding and blood transfusion during pelvic surgery." | 4.90 | The effects of lysine analogs during pelvic surgery: a systematic review and meta-analysis. ( Beck, A; Breau, RH; Buenaventura, C; Cagiannos, I; Cowan, J; Fergusson, DA; Knoll, G; Kokolo, MB; Momoli, F; Morash, C; Niznick, N; Punjani, N; Ruzicka, M; Schachkina, S; Tinmouth, A; Xie, HY, 2014) |
| "Tranexamic acid safely reduces mortality in bleeding trauma patients without increasing the risk of adverse events." | 4.88 | Antifibrinolytic drugs for acute traumatic injury. ( Coats, T; Ker, K; Roberts, I; Shakur, H, 2012) |
| "We conducted a secondary analysis of the MAssive Transfusion in Children (MATIC), a prospectively collected database of children with life-threatening hemorrhage (LTH), and evaluated for risk of adverse events with either antifibrinolytic treatment, epsilon aminocaproic acid (EACA) or tranexamic acid (TXA)." | 4.31 | Epsilon aminocaproic acid is associated with acute kidney injury after life-threatening hemorrhage in children. ( Josephson, CD; Kolodziej, JH; Leeper, CM; Leonard, JC; Spinella, PC; Zenati, MS, 2023) |
| "This multicenter international experience of pediatric craniofacial surgery reports no increase in seizures or thromboembolic events in those that received antifibrinolytics (tranexamic acid and epsilon-aminocaproic acid) versus those that did not." | 4.12 | Safety of antifibrinolytics in 6583 pediatric patients having craniosynostosis surgery: A decade of data reported from the multicenter Pediatric Craniofacial Collaborative Group. ( Benzon, HA; Goobie, SM; King, MR; Nelson, O; Pérez-Pradilla, C; Staffa, SJ; Stricker, PA, 2022) |
| "A prospective study evaluating the efficacy of epsilon-aminocaproic acid (EACA) in decreasing perioperative blood loss in idiopathic scoliosis." | 3.71 | The Effect of epsilon-aminocaproic acid on perioperative blood loss in patients with idiopathic scoliosis undergoing posterior spinal fusion: a preliminary prospective study. ( Adler, P; Blakemore, LC; Florentino-Pineda, I; Poe-Kochert, C; Thompson, GH; Tripi, P, 2001) |
| "ε-Aminocaproic acid (EACA) is an antifibrinolytic agent that has been shown to decrease blood loss and transfusion requirements in several populations undergoing various surgical procedures." | 2.94 | Effect of Intravenous Aminocaproid Acid on Blood Loss and Transfusion Requirements After Bilateral Varus Rotational Osteotomy: A Double-blind, Placebo-controlled Randomized Trial. ( Dodwell, E; Edmonds, C; Nguyen, J; Scher, D; Swarup, I, 2020) |
| " As sufficient data are lacking, large comparative trials are warranted to assess the relative safety and appropriate dosing regimens in pediatrics." | 2.82 | Antifibrinolytic Drugs for the Prevention of Bleeding in Pediatric Cardiac Surgery on Cardiopulmonary Bypass: A Systematic Review and Meta-analysis. ( Hunt, BJ; Murdoch, IA; Sangaran, DP; Siemens, K; Tibby, SM, 2022) |
| "When dosed in a pharmacologically guided manner, EACA is not inferior to aprotinin in reducing fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery." | 2.74 | The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized, double-blind, placebo-controlled, noninferiority trial. ( Beckham, JM; Butterworth, JF; Greilich, PE; Jessen, ME; Nuttall, GA; Satyanarayana, N; Wall, MH; Whitten, CW, 2009) |
| "All antifibrinolytic drugs reduced postoperative blood loss and transfusions when used in pediatric surgery." | 2.72 | Efficacy and Safety of Antifibrinolytic Drugs in Pediatric Surgery: A Systematic Review. ( Fenger-Eriksen, C; Hansen, AK; Hovgesen, NT; Hvas, AM; Larsen, JB, 2021) |
| " However, more large-scale trials are needed to examine the long-term adverse side effects of EACA in spinal fusion surgery." | 2.72 | The Efficacy and Safety of Epsilon-Aminocaproic Acid for Perioperative Blood Management in Spinal Fusion Surgery: A Systematic Review and Meta-Analysis. ( Cen, Y; Li, S; Xing, F; Zhang, Z, 2021) |
| "Sixty-nine adults with malignancy scheduled for either pelvic, extremity or spine surgery during general anesthesia entered this randomized, double-blind, placebo-controlled trial, and received either intravenous aprotinin (n = 23), bolus of 2 x 10(6) kallikrein inactivator units (KIU), followed by an infusion of 5 x 10(5) KIU/h, or EACA (n = 22), bolus of 150 mg/kg, followed by a 15 mg/kg/h infusion or saline placebo (n = 24) during surgery." | 2.71 | Antifibrinolytic therapy and perioperative blood loss in cancer patients undergoing major orthopedic surgery. ( Amar, D; Boland, PJ; Grant, FM; Healey, JA; Leung, DH; Zhang, H, 2003) |
| " Levels of S-100beta and neuron-specific enolase were similar with both therapies, confirming that there was no difference in the occurrence of any adverse neurologic events in either group." | 2.70 | Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost. ( O'Brien, MF; Ray, MJ, 2001) |
| "This meta-analysis demonstrated that EACA could be safe and potentially efficacious for reducing blood loss and transfusions volume in patients with spinal deformity surgeries when compared with placebo." | 2.61 | The Efficacy and Safety of Epsilon-Aminocaproic Acid for Blood Loss and Transfusions in Spinal Deformity Surgery: A Meta-Analysis. ( Chen, R; Gong, M; Xiang, Z, 2019) |
| "Based on the present meta-analysis, intravenous aminocaproic acid is effective and safe in total knee and hip arthroplasty without increasing the incidence of thromboembolic events." | 2.58 | The effectiveness and safety of aminocaproic acid for reducing blood loss in total knee and hip arthroplasty: A meta-analysis. ( Dong, Q; Hu, F; Sun, X; Zhang, Y, 2018) |
| "A total of 59 participants with haemophilia undergoing dental extraction were involved." | 2.55 | Preventing perioperative bleeding in patients with inherited bleeding disorders. ( Beacher, N; Watterson, C, 2017) |
| "The safety of lysine analogues in cancer patients has not been extensively studied." | 2.55 | The Safety and Efficacy of Lysine Analogues in Cancer Patients: A Systematic Review and Meta-Analysis. ( Breau, RH; Cagiannos, I; Cnossen, S; Fergusson, DA; Fergusson, NA; Hutton, B; Lavallée, LT; Montroy, J; Morash, C, 2017) |
| "In people with haemophilia or other congenital bleeding disorders undergoing surgical interventions, haemostatic treatment is needed in order to correct the underlying coagulation abnormalities and minimise the bleeding risk." | 2.52 | Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery. ( Coppola, A; Di Minno, MN; Tufano, A; Windyga, J; Yeung, C, 2015) |
| "TXA safely reduces mortality in trauma patients with bleeding without increasing the risk of adverse events." | 2.52 | Antifibrinolytic drugs for acute traumatic injury. ( Coats, TJ; Ker, K; Roberts, I; Shakur, H, 2015) |
| " Although TXA is a long known drug available on the market for more than 50 years, the studies connecting factors of indication, dosage regimen and safety are limited especially in children and infants." | 2.49 | [Hemostasis and antifibrinolytic therapy in major pediatric surgery]. ( Hertfelder, HJ; Schindler, E, 2013) |
| " Further studies are needed to adjust dosage of EACA to make better comparison of the two drugs." | 1.91 | Combination of Intravenous and Intra-Articular Application of Tranexamic Acid and Epsilon-Aminocaproic Acid in Primary Total Knee Arthroplasty: A Prospective Randomized Controlled Trial. ( Li, M; Liu, Y; Ma, J; Shen, B; Si, H; Xu, J; Zheng, C, 2023) |
| "Tranexamic acid (TXA) has long been the antifibrinolytic hemostatic drug of choice for orthopedic surgery." | 1.91 | Efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs. ( Haibier, A; Qin, Q; Ran, J; Ren, Z; Yusufu, A; Zhang, Z; Zhou, Y, 2023) |
| " Weight-based TXA dosing regimens have been compared to fixed-dose regimens of EACA with variable outcomes in perioperative blood product transfusions and chest tube output." | 1.72 | Comparison of trauma-dosed tranexamic acid versus aminocaproic acid in cardiac surgery in the setting of drug shortage. ( Cook, BM; Dannemiller, RE; Goodberlet, MZ; Kelly, JM; Knowles, DM; Malloy, R, 2022) |
| "The purpose of this study was to determine if a higher dosing of ε-aminocaproic acid (EACA) is associated with less perioperative blood loss than a lower dose." | 1.51 | Unexpected higher blood loss associated with higher dose ε-aminocaproic acid in pediatric scoliosis surgery. ( Austin, T; Lam, H; Martus, J; Nguyen, T; Schoenecker, J, 2019) |
| "Tranexamic acid (TXA) was found to be more effective at reducing total blood loss compared with epsilon-aminocaproic acid (AM) than placebo." | 1.48 | Antifibrinolytic Therapy in Surgery for Adolescent Idiopathic Scoliosis Does the Level 1 Evidence Translate to Practice? ( Asghar, J; Lonner, BS; Newton, PO; Ren, Y; Samdani, AF; Shah, SA, 2018) |
| "Using a standardized dosing regimen of EACA during craniosynostosis surgery, we found statistical significance in blood loss and transfusion requirements in surgeries of the shortest duration." | 1.46 | Blood loss and transfusion requirements with epsilon-aminocaproic acid use during cranial vault reconstruction surgery. ( Demke, J; Nagy, L; Saadeh, C; Thompson, ME; Watkins, P, 2017) |
| " Antifibrinolytic dosage regimes should be based on pharmacokinetic data avoiding high doses." | 1.46 | Safety of antifibrinolytics in cranial vault reconstructive surgery: a report from the pediatric craniofacial collaborative group. ( Cladis, FP; Fernandez, AM; Glover, CD; Goobie, SM; Huang, H; Reddy, SK; Stricker, PA; Zurakowski, D, 2017) |
| "Cranial vault remodeling (CVR) for craniosynostosis is a procedure with the potential for significant blood loss." | 1.40 | Minimizing transfusions in primary cranial vault remodeling: the role of aminocaproic acid. ( Buchman, SR; Kapurch, J; Levi, B; Muraszko, KM; Oppenheimer, AJ; Ranganathan, K; Strahle, JM, 2014) |
| "Postoperative seizures occurred significantly more frequently in TXA patients (7." | 1.37 | Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid. ( Breuer, T; Gertler, R; Knorr, J; Lange, R; Macguill, M; Martin, K; Tassani, P; Wiesner, G, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.68) | 18.7374 |
| 1990's | 26 (17.81) | 18.2507 |
| 2000's | 34 (23.29) | 29.6817 |
| 2010's | 59 (40.41) | 24.3611 |
| 2020's | 26 (17.81) | 2.80 |
| Authors | Studies |
|---|---|
| Li, S | 1 |
| Xing, F | 1 |
| Cen, Y | 1 |
| Zhang, Z | 2 |
| Siemens, K | 1 |
| Sangaran, DP | 1 |
| Hunt, BJ | 1 |
| Murdoch, IA | 1 |
| Tibby, SM | 1 |
| Ahlers, CG | 1 |
| Lan, M | 1 |
| Schoenecker, JG | 1 |
| Borst, AJ | 2 |
| Li, Z | 1 |
| Sun, X | 2 |
| Li, W | 1 |
| Zhang, M | 1 |
| Zhong, L | 1 |
| Xu, Y | 1 |
| Wang, Y | 1 |
| Liu, Y | 5 |
| Huang, Q | 1 |
| Fan, XL | 1 |
| Zhang, J | 1 |
| Yang, ZQ | 1 |
| Kelava, M | 1 |
| Mehta, A | 1 |
| Sale, S | 1 |
| Gillinov, M | 1 |
| Johnston, D | 1 |
| Thuita, L | 1 |
| Kumar, N | 1 |
| Blackstone, EH | 1 |
| Dannemiller, RE | 1 |
| Knowles, DM | 1 |
| Cook, BM | 1 |
| Goodberlet, MZ | 1 |
| Kelly, JM | 1 |
| Malloy, R | 1 |
| King, MR | 1 |
| Staffa, SJ | 1 |
| Stricker, PA | 5 |
| Pérez-Pradilla, C | 1 |
| Nelson, O | 1 |
| Benzon, HA | 1 |
| Goobie, SM | 2 |
| Xie, H | 3 |
| Yang, YS | 3 |
| Tian, SM | 3 |
| Wang, BJ | 3 |
| Fu, WM | 3 |
| Cheng, LL | 3 |
| Jiang, NN | 3 |
| Gu, G | 3 |
| Zhao, DW | 3 |
| Zheng, C | 4 |
| Ma, J | 4 |
| Xu, J | 4 |
| Wu, L | 3 |
| Wu, Y | 3 |
| Shen, B | 4 |
| Si, H | 1 |
| Li, M | 3 |
| Kolodziej, JH | 1 |
| Leeper, CM | 1 |
| Leonard, JC | 1 |
| Josephson, CD | 1 |
| Zenati, MS | 1 |
| Spinella, PC | 1 |
| Tanis-Arens, CE | 1 |
| Mastropietro, CM | 1 |
| Walker, SG | 1 |
| Abbasi, RK | 1 |
| Yusufu, A | 1 |
| Haibier, A | 1 |
| Ren, Z | 1 |
| Qin, Q | 1 |
| Zhou, Y | 1 |
| Ran, J | 1 |
| Butt, AL | 1 |
| Stewart, KE | 1 |
| Kyo, H | 1 |
| Tanaka, KA | 2 |
| Li, J | 1 |
| Guo, Y | 1 |
| Bradley, KE | 1 |
| Ryan, SP | 1 |
| Penrose, CT | 1 |
| Grant, SA | 1 |
| Wellman, SS | 2 |
| Attarian, DE | 1 |
| Green, CL | 2 |
| Risoli, T | 1 |
| Bolognesi, MP | 1 |
| Lonner, BS | 3 |
| Ren, Y | 1 |
| Asghar, J | 1 |
| Shah, SA | 2 |
| Samdani, AF | 2 |
| Newton, PO | 2 |
| Zhang, R | 1 |
| Yang, Z | 1 |
| Lei, T | 1 |
| Ping, Z | 1 |
| Bai, G | 1 |
| Tripathy, SK | 1 |
| Rao, PB | 1 |
| Nanda, SN | 1 |
| Nayak, C | 1 |
| Samal, BP | 1 |
| Jain, M | 1 |
| Srinivasan, A | 1 |
| Hota, D | 1 |
| Swarup, I | 1 |
| Nguyen, J | 1 |
| Edmonds, C | 1 |
| Dodwell, E | 1 |
| Scher, D | 1 |
| Pillutla, P | 1 |
| Le, A | 1 |
| Thompson, ME | 2 |
| Watkins, P | 2 |
| Nagy, L | 2 |
| Demke, JC | 1 |
| Bolliger, D | 1 |
| Erb, JM | 1 |
| Montroy, J | 2 |
| Hutton, B | 3 |
| Fergusson, DA | 5 |
| Tinmouth, A | 3 |
| Lavallée, LT | 2 |
| Cagiannos, I | 3 |
| Morash, C | 3 |
| Flaman, A | 1 |
| Breau, RH | 3 |
| Bonfield, CM | 1 |
| Deenadayalan, PS | 1 |
| Le, CH | 1 |
| Xu, M | 1 |
| Sobey, JH | 1 |
| Reddy, SK | 2 |
| Hovgesen, NT | 1 |
| Larsen, JB | 1 |
| Fenger-Eriksen, C | 1 |
| Hansen, AK | 1 |
| Hvas, AM | 1 |
| Watterson, C | 1 |
| Beacher, N | 1 |
| Fergusson, NA | 1 |
| Cnossen, S | 1 |
| Hobbs, JC | 1 |
| Welsby, IJ | 1 |
| Dhakal, IB | 1 |
| Harper, RA | 1 |
| Sucher, MG | 2 |
| Giordani, M | 2 |
| Nedopil, AJ | 2 |
| Boese, CK | 1 |
| Centeno, L | 1 |
| Walters, RW | 1 |
| Hardesty, CK | 1 |
| Gordon, ZL | 1 |
| Poe-Kochert, C | 6 |
| Son-Hing, JP | 2 |
| Thompson, GH | 6 |
| Dong, Q | 1 |
| Zhang, Y | 1 |
| Hu, F | 1 |
| Ramkumar, DB | 1 |
| Ramkumar, N | 1 |
| Tapp, SJ | 1 |
| Moschetti, WE | 1 |
| Liu, Q | 1 |
| Geng, P | 1 |
| Shi, L | 1 |
| Wang, Q | 1 |
| Wang, P | 1 |
| Brignardello-Petersen, R | 1 |
| Lam, H | 1 |
| Austin, T | 1 |
| Nguyen, T | 1 |
| Martus, J | 1 |
| Schoenecker, J | 2 |
| Faraoni, D | 1 |
| Rahe, C | 1 |
| Cybulski, KA | 1 |
| Siotou, K | 1 |
| Siotos, C | 1 |
| Azizi, A | 1 |
| Cheah, MA | 1 |
| Seal, SM | 1 |
| Redett, RJ | 1 |
| Rosson, GD | 1 |
| Li, Y | 1 |
| Wang, J | 1 |
| Chen, R | 1 |
| Xiang, Z | 1 |
| Gong, M | 1 |
| Raveh, Y | 1 |
| Shatz, V | 1 |
| Lindsay, M | 1 |
| Nicolau-Raducu, R | 1 |
| Nguyen, TT | 1 |
| Lam, HV | 1 |
| Austin, TM | 1 |
| Stricker, P | 1 |
| Tunceroglu, H | 1 |
| Riaz, O | 1 |
| Aqil, A | 1 |
| Asmar, S | 1 |
| Vanker, R | 1 |
| Hahnel, J | 1 |
| Brew, C | 1 |
| Grogan, R | 1 |
| Radcliffe, G | 1 |
| Roberts, I | 2 |
| Shakur, H | 2 |
| Ker, K | 4 |
| Coats, T | 1 |
| Gurian, DB | 1 |
| Meneghini, A | 1 |
| Abreu, LC | 1 |
| Murad, N | 1 |
| Matos, LL | 1 |
| Pires, AC | 1 |
| Valenti, VE | 1 |
| Breda, JR | 1 |
| Ortmann, E | 1 |
| Besser, MW | 1 |
| Klein, AA | 1 |
| Schindler, E | 1 |
| Hertfelder, HJ | 1 |
| Iorio, J | 1 |
| Bennett, JT | 1 |
| Orlando, G | 1 |
| Singla, A | 1 |
| Dakwar, E | 1 |
| Bonet, H | 1 |
| Makhija, N | 1 |
| Sarupria, A | 1 |
| Kumar Choudhary, S | 1 |
| Das, S | 1 |
| Lakshmy, R | 2 |
| Kiran, U | 1 |
| Oppenheimer, AJ | 1 |
| Ranganathan, K | 1 |
| Levi, B | 1 |
| Strahle, JM | 1 |
| Kapurch, J | 1 |
| Muraszko, KM | 1 |
| Buchman, SR | 1 |
| Scott, JP | 1 |
| Costigan, DJ | 1 |
| Hoffman, GM | 1 |
| Simpson, PM | 1 |
| Dasgupta, M | 1 |
| Punzalan, R | 1 |
| Berens, RJ | 1 |
| Tweddell, JS | 1 |
| Stuth, EA | 1 |
| Verma, K | 3 |
| Errico, T | 2 |
| Diefenbach, C | 1 |
| Hoelscher, C | 2 |
| Peters, A | 2 |
| Dryer, J | 1 |
| Huncke, T | 2 |
| Boenigk, K | 1 |
| Kokolo, MB | 1 |
| Punjani, N | 1 |
| Beck, A | 1 |
| Niznick, N | 1 |
| Buenaventura, C | 1 |
| Cowan, J | 1 |
| Knoll, G | 1 |
| Momoli, F | 1 |
| Ruzicka, M | 1 |
| Schachkina, S | 1 |
| Xie, HY | 1 |
| Cuellar, JM | 1 |
| Yoo, A | 1 |
| Tovar, N | 1 |
| Coelho, PG | 1 |
| Jimbo, R | 1 |
| Vandeweghe, S | 1 |
| Kirsch, T | 1 |
| Quirno, M | 1 |
| Errico, TJ | 3 |
| Falana, O | 1 |
| Patel, G | 1 |
| Slobodyanyuk, K | 1 |
| Cheriyan, T | 1 |
| Schwab, F | 1 |
| Lonner, B | 1 |
| Lafage, V | 2 |
| Coppola, A | 1 |
| Windyga, J | 1 |
| Tufano, A | 1 |
| Yeung, C | 1 |
| Di Minno, MN | 1 |
| Coats, TJ | 1 |
| Hsu, G | 1 |
| Taylor, JA | 3 |
| Fiadjoe, JE | 2 |
| Vincent, AM | 1 |
| Pruitt, EY | 2 |
| Bartlett, SP | 2 |
| McLawhorn, AS | 1 |
| Levack, AE | 1 |
| Fields, KG | 1 |
| Sheha, ED | 1 |
| DelPizzo, KR | 1 |
| Sink, EL | 1 |
| van Galen, KP | 1 |
| Engelen, ET | 1 |
| Mauser-Bunschoten, EP | 1 |
| van Es, RJ | 1 |
| Schutgens, RE | 1 |
| Figoni, A | 1 |
| Churchill, JL | 1 |
| Puca, KE | 1 |
| Meyer, ES | 1 |
| Carleton, MC | 1 |
| Truchan, SL | 1 |
| Anderson, MJ | 1 |
| Soroceanu, A | 1 |
| Oren, JH | 1 |
| Smith, JS | 1 |
| Hostin, R | 1 |
| Shaffrey, CI | 1 |
| Mundis, GM | 1 |
| Ames, CP | 1 |
| Burton, DC | 1 |
| Bess, S | 1 |
| Gupta, MC | 1 |
| Deviren, V | 1 |
| Schwab, FJ | 1 |
| Saadeh, C | 1 |
| Demke, J | 1 |
| Cladis, FP | 1 |
| Glover, CD | 1 |
| Huang, H | 1 |
| Fernandez, AM | 1 |
| Zurakowski, D | 1 |
| Florentino-Pineda, I | 5 |
| Armstrong, DG | 2 |
| Gill, JB | 1 |
| Chin, Y | 1 |
| Levin, A | 1 |
| Feng, D | 1 |
| Son-Hing, J | 1 |
| Henry, D | 1 |
| Carless, P | 1 |
| Fergusson, D | 3 |
| Laupacis, A | 2 |
| Greilich, PE | 1 |
| Jessen, ME | 1 |
| Satyanarayana, N | 1 |
| Whitten, CW | 1 |
| Nuttall, GA | 1 |
| Beckham, JM | 1 |
| Wall, MH | 1 |
| Butterworth, JF | 1 |
| Berenholtz, SM | 1 |
| Pham, JC | 1 |
| Garrett-Mayer, E | 1 |
| Atchison, CW | 1 |
| Kostuik, JP | 1 |
| Cohen, DB | 1 |
| Nundy, S | 1 |
| Dorman, T | 1 |
| Ness, PM | 1 |
| Klag, MJ | 1 |
| Pronovost, PJ | 1 |
| Kebaish, KM | 1 |
| Eubanks, JD | 1 |
| Vaz, KM | 1 |
| Raghunathan, K | 1 |
| Connelly, NR | 1 |
| Kanter, GJ | 1 |
| Rahman, Z | 1 |
| Hoque, R | 1 |
| Ali, A | 1 |
| Rahman, M | 1 |
| Rahman, MS | 1 |
| Henry, DA | 3 |
| Carless, PA | 3 |
| Moxey, AJ | 3 |
| O'Connell, D | 2 |
| Stokes, BJ | 3 |
| Beattie, WS | 1 |
| Karkouti, K | 1 |
| Martin, K | 3 |
| Knorr, J | 1 |
| Breuer, T | 1 |
| Gertler, R | 3 |
| Macguill, M | 3 |
| Lange, R | 1 |
| Tassani, P | 3 |
| Wiesner, G | 3 |
| Sterner, A | 1 |
| Schreiber, C | 1 |
| Hörer, J | 2 |
| Vogt, M | 2 |
| Dhawale, AA | 1 |
| Sponseller, PD | 1 |
| Bastrom, T | 1 |
| Neiss, G | 1 |
| Yorgova, P | 1 |
| Yaszay, B | 1 |
| Abel, MF | 1 |
| Shufflebarger, H | 1 |
| Gabos, PG | 1 |
| Dabney, KW | 1 |
| Miller, F | 1 |
| Banerjee, A | 1 |
| Stoica, C | 1 |
| Walia, A | 1 |
| Basta, MN | 1 |
| Joseph, L | 1 |
| Mazer, CD | 2 |
| Shapiro, S | 1 |
| Mayr, NP | 1 |
| Hapfelmeier, A | 1 |
| Zuppa, AF | 1 |
| Maxwell, LG | 1 |
| Sussman, EM | 1 |
| Goebel, TK | 1 |
| Gastonguay, MR | 1 |
| Schreiner, MS | 1 |
| Amar, D | 1 |
| Grant, FM | 1 |
| Zhang, H | 1 |
| Boland, PJ | 1 |
| Leung, DH | 1 |
| Healey, JA | 1 |
| Rothwell, SW | 1 |
| Fudge, JM | 1 |
| Reid, TJ | 1 |
| Krishnamurti, C | 1 |
| CHARMASSON, R | 1 |
| Kluger, R | 1 |
| Olive, DJ | 1 |
| Stewart, AB | 1 |
| Blyth, CM | 1 |
| Huang, RP | 1 |
| Haber, LL | 1 |
| Blakemore, LC | 2 |
| Tobias, JD | 1 |
| Arora, RC | 1 |
| Légaré, JF | 1 |
| Buth, KJ | 1 |
| Sullivan, JA | 1 |
| Hirsch, GM | 1 |
| Shore-Lesserson, L | 1 |
| Bodian, C | 1 |
| Vela-Cantos, F | 1 |
| Silvay, G | 1 |
| Reich, DL | 1 |
| Kikura, M | 1 |
| Levy, JH | 1 |
| Ramsay, JG | 1 |
| Camarasa, MA | 1 |
| Ollé, G | 1 |
| Serra-Prat, M | 2 |
| Martín, A | 1 |
| Sánchez, M | 1 |
| Ricós, P | 1 |
| Pérez, A | 1 |
| Opisso, L | 1 |
| Martínez Rodríguez, E | 1 |
| Mato, M | 1 |
| Otero, J | 1 |
| Ferri, JR | 1 |
| Gonzálvez, A | 1 |
| Torres, LM | 1 |
| Sharma, V | 1 |
| Talwar, S | 1 |
| Choudhary, SK | 1 |
| Kale, S | 1 |
| Kumar, AS | 1 |
| Groenland, TH | 1 |
| Porte, RJ | 1 |
| Alberca, I | 1 |
| Asuero, MS | 1 |
| Bóveda, JL | 1 |
| Carpio, N | 1 |
| Contreras, E | 1 |
| Fernández-Mondéjar, E | 1 |
| Forteza, A | 1 |
| García-Erce, JA | 1 |
| García de Lorenzo, A | 1 |
| Gomar, C | 1 |
| Gómez, A | 1 |
| Llau, JV | 1 |
| López-Fernández, MF | 1 |
| Moral, V | 1 |
| Muñoz, M | 1 |
| Páramo, JA | 1 |
| Torrabadella, P | 1 |
| Quintana, M | 1 |
| Sánchez, C | 1 |
| Body, SC | 1 |
| Gunaydin, B | 1 |
| Ozkose, Z | 1 |
| Pezek, S | 1 |
| Camarasa Godoy, MA | 1 |
| Palomera Fanegas, E | 1 |
| Dorman, BH | 1 |
| Stroud, RE | 1 |
| Wyckoff, MM | 1 |
| Zellner, JL | 1 |
| Botta, D | 1 |
| Leonardi, AH | 1 |
| Ikonomidis, JS | 1 |
| Spinale, FG | 1 |
| Trudell, J | 1 |
| McMurdy, N | 1 |
| Fremes, SE | 1 |
| Wong, BI | 1 |
| Lee, E | 1 |
| Mai, R | 1 |
| Christakis, GT | 1 |
| McLean, RF | 1 |
| Goldman, BS | 1 |
| Naylor, CD | 1 |
| Hardy, JF | 2 |
| Bélisle, S | 2 |
| Peterson, KL | 1 |
| DeCampli, WM | 1 |
| Feeley, TW | 1 |
| Starnes, VA | 1 |
| Royston, D | 2 |
| Penta de Peppo, A | 1 |
| Pierri, MD | 1 |
| Scafuri, A | 1 |
| De Paulis, R | 1 |
| Colantuono, G | 1 |
| Caprara, E | 1 |
| Tomai, F | 1 |
| Chiariello, L | 1 |
| Chen, RH | 1 |
| Frazier, OH | 1 |
| Cooley, DA | 1 |
| Aprile, AE | 1 |
| Palmer, TJ | 1 |
| Jordan, D | 1 |
| Delphin, E | 1 |
| Rose, E | 1 |
| Daily, PO | 1 |
| Lamphere, JA | 1 |
| Dembitsky, WP | 1 |
| Adamson, RM | 1 |
| Dans, NF | 1 |
| Karski, JM | 1 |
| Teasdale, SJ | 2 |
| Norman, PH | 1 |
| Carroll, JA | 1 |
| Weisel, RD | 2 |
| Glynn, MF | 2 |
| Arom, KV | 1 |
| Emery, RW | 1 |
| Kang, Y | 1 |
| Harmon, DE | 1 |
| Menichetti, A | 1 |
| Tritapepe, L | 1 |
| Ruvolo, G | 1 |
| Speziale, G | 1 |
| Cogliati, A | 1 |
| Di Giovanni, C | 1 |
| Pacilli, M | 1 |
| Criniti, A | 1 |
| Radivoyevitch, MA | 1 |
| Bennett-Guerrero, E | 1 |
| Sorohan, JG | 1 |
| Gurevich, ML | 1 |
| Kazanjian, PE | 1 |
| Levy, RR | 1 |
| Barberá, AV | 1 |
| White, WD | 1 |
| Slaughter, TF | 1 |
| Sladen, RN | 1 |
| Smith, PK | 1 |
| Newman, MF | 1 |
| Dupont, C | 1 |
| Harel, F | 1 |
| Robitaille, D | 1 |
| Roy, M | 1 |
| Gagnon, L | 1 |
| Perazella, MA | 1 |
| Biswas, P | 1 |
| Williams, GD | 1 |
| Bratton, SL | 1 |
| Riley, EC | 1 |
| Ramamoorthy, C | 1 |
| Casati, V | 1 |
| Guzzon, D | 1 |
| Oppizzi, M | 1 |
| Cossolini, M | 1 |
| Torri, G | 1 |
| Calori, G | 1 |
| Alfieri, O | 1 |
| Rao, BH | 2 |
| Saxena, N | 2 |
| Chauhan, S | 2 |
| Bisoi, AK | 1 |
| Venugopal, P | 2 |
| Dalmau, A | 1 |
| Sabaté, A | 1 |
| Acosta, F | 1 |
| Garcia-Huete, L | 1 |
| Koo, M | 1 |
| Sansano, T | 1 |
| Rafecas, A | 1 |
| Figueras, J | 1 |
| Jaurrieta, E | 1 |
| Parrilla, P | 1 |
| Cattaneo, M | 1 |
| Mannucci, PM | 1 |
| Kumar, BA | 1 |
| Rao, MS | 1 |
| Dubey, B | 1 |
| Ray, MJ | 1 |
| O'Brien, MF | 1 |
| Adler, P | 1 |
| Tripi, P | 1 |
| Urban, MK | 1 |
| Beckman, J | 1 |
| Gordon, M | 1 |
| Urquhart, B | 1 |
| Boachie-Adjei, O | 1 |
| Harley, BJ | 1 |
| Beaupré, LA | 1 |
| Jones, CA | 1 |
| Cinats, JG | 1 |
| Guenther, CR | 1 |
| Trinh-Duc, P | 1 |
| Wintrebert, P | 1 |
| Boulfroy, D | 1 |
| Albat, B | 1 |
| Thévenet, A | 1 |
| Roquefeuil, B | 1 |
| Yau, TM | 1 |
| Carson, S | 1 |
| Ivanov, J | 1 |
| Sun, Z | 1 |
| Yu, R | 1 |
| McSorley, MW | 1 |
| Taraporewalla, KJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Study of the Efficiency of Oral Tranexamic Tcid vs. Oral Tminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement. A Prospective, Randomized, Double Blinded Controlled Clinical Trial.[NCT03365999] | Phase 2 | 92 participants (Actual) | Interventional | 2017-10-15 | Completed | ||
| Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss, Transfusion Index and Complications After Total Hip Replacement. A Prospective, Randomized, Double Blind Clinical Trial[NCT04187014] | Phase 2 | 90 participants (Actual) | Interventional | 2020-02-06 | Completed | ||
| Evaluation of the Minimum Concentration of Tranexamic Acid Required to Inhibit Fibrinolysis in a Population of Pregnant Women at Term.[NCT02579941] | 40 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Prophylactic Use of Topical Tranexamic Acid to Aid Surgical Haemostasis During Caesarean Sections in Parturients With Moderate to High Risk of Bleeding[NCT02492087] | Phase 3 | 84 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491] | Phase 3 | 11,000 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
| Efficacy of ε-Aminocaproic Acid (EACA) in Children Undergoing Craniofacial Reconstruction Surgery[NCT02229968] | Phase 2 | 22 participants (Actual) | Interventional | 2014-10-31 | Active, not recruiting | ||
| Pilot RCT: Use of Tranexamic Acid (TXA) in Post Mastectomy Patients for Seroma and Hematoma Prevention[NCT03738527] | Phase 4 | 100 participants (Anticipated) | Interventional | 2019-10-07 | Recruiting | ||
| Low Versus High Dose Tranexamic Acid in Adult Spinal Deformity Surgery: A Randomized, Blinded, Controlled Trial[NCT02053363] | Phase 2/Phase 3 | 64 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Topical Application of Tranexamic Acid to Reduce Postoperative Blood Loss in Posterior Approach Spinal Surgery[NCT02063035] | Phase 4 | 29 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| The Effect of Intravenous E-Aminocaproic Acid (EACA) on Blood Loss and Transfusion Requirements After Bilateral Varus Rotational Osteotomy (VRO)[NCT02257580] | Phase 4 | 28 participants (Actual) | Interventional | 2015-04-01 | Completed | ||
| The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery[NCT01728636] | Phase 2 | 61 participants (Actual) | Interventional | 2013-01-15 | Completed | ||
| Aminocaproic Acid and Bleeding in Spinal Surgery[NCT00320619] | 182 participants (Actual) | Interventional | 2000-09-30 | Completed | |||
| Role of Topical Tranexamic Acid in Total Hip Arthroplasty[NCT01866943] | Phase 2 | 41 participants (Actual) | Interventional | 2011-11-30 | Terminated | ||
| Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty: A Randomized Controlled Trial[NCT02829346] | Phase 2 | 60 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Evaluation of Tranexamic Acid Prior to Surgery in the Geriatric Hip Fracture Population for the Reduction of Post-Operative Blood Transfusion[NCT03923959] | Phase 3 | 400 participants (Anticipated) | Interventional | 2020-02-01 | Active, not recruiting | ||
| A Prospective, Randomized, Double-blinded Single-site Control Study Comparing Blood Loss Prevention of Tranexamic Acid (TXA) to Epsilon Aminocaproic Acid (EACA) for Corrective Spinal Surgery[NCT00958581] | Phase 4 | 177 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Randomized Control Trial Investigating for Prophylactic Tranexamic Acid Use at Time of Minimally Invasive Myomectomies[NCT04311073] | Phase 3 | 50 participants (Anticipated) | Interventional | 2020-06-20 | Recruiting | ||
| Use of TRanEXamic Acid in Reduction Mammoplasty (TREX-ARM): a Double-blinded Randomized Controlled Trial[NCT04947514] | Phase 4 | 98 participants (Actual) | Interventional | 2021-10-29 | Completed | ||
| Single Centre Randomised Controlled Trial to Assess the Effect of the Addition of Twenty-four Hours of Oral Tranexamic Acid Post-operatively to a Single Intra-operative Intravenous Dose of Tranexamic Acid on Calculated Blood Loss Following Primary Hip and[NCT03690037] | Phase 4 | 1,089 participants (Actual) | Interventional | 2016-07-07 | Completed | ||
| Outcome Impact of Different Tranexamic Acid Regimen in Cardiac Surgery With Cardiopulmonary Bypass (the OPTIMAL Study)[NCT03782350] | Phase 4 | 3,079 participants (Actual) | Interventional | 2018-12-26 | Completed | ||
| Peroperative Tranexamic Acid as Prophylaxis of Haemorrhage in Benign Hysterectomy - a Randomized, Placebo-controlled Trial[NCT01940419] | Phase 4 | 332 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| IV Tranexamic Acid Prior to Hysterectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial[NCT02911831] | Early Phase 1 | 71 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Evaluation of the Safety and Efficacy of the Second Dose of Tranexamic Acid Administration of Trauma Patients: A Randomized, Double-blind Controlled Clinical Trial[NCT03846973] | Phase 3 | 220 participants (Actual) | Interventional | 2018-12-02 | Completed | ||
| Comparative Use of Tranexamic Acid Intravenous and Topical Application in the Treatment of Intertrochanteric Fractures With Proximate Femoral Nail[NCT04696224] | 90 participants (Anticipated) | Interventional | 2020-12-18 | Recruiting | |||
| A Prospective, Randomized, Single-blinded, Non-inferiority Study to Evaluate the Safety and Efficacy of the Saline-coupled Bipolar Sealer Compared to the Unipolar Electrocautery in Primary Unilateral Total Knee Arthroplasty[NCT03952546] | 211 participants (Actual) | Interventional | 2019-05-07 | Completed | |||
| Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty[NCT03825939] | Phase 4 | 52 participants (Actual) | Interventional | 2015-04-21 | Terminated (stopped due to Lack of patient enrollment due to only one surgeon that was enrolling.) | ||
| Intravenous Tranexamic Acid to Reduce Blood Loss in Reverse Total Shoulder Arthroplasty[NCT02043132] | Phase 2/Phase 3 | 116 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| The Effect of Tranexamic Acid on Intraoperative and Post-Operative Bleeding in Functional Endoscopic Sinus Surgery: A Randomized, Prospective, Double-Blinded Study[NCT00671281] | 74 participants (Anticipated) | Interventional | 2008-10-31 | Withdrawn (stopped due to Study was cancelled) | |||
| Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599] | 40 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| Role of Tranexamic Acid for Reducing Blood Loss in Patients Undergoing Major Gastro-intestinal Surgery[NCT01655641] | Phase 2/Phase 3 | 118 participants (Anticipated) | Interventional | 2012-07-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum
| Intervention | grams per deciliter (Mean) |
|---|---|
| Tranexamic Acid | -1.8 |
| Placebo | -1.9 |
Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days
| Intervention | days (Median) |
|---|---|
| Tranexamic Acid | 3 |
| Placebo | 3 |
(NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 35 |
| Placebo | 32 |
This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 108 |
| Placebo | 109 |
This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 233 |
| Placebo | 231 |
[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 892 |
| Placebo | 986 |
Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 20 |
| Placebo | 19 |
This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 29 |
| Placebo | 31 |
This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 649 |
| Placebo | 732 |
[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 12 |
| Placebo | 13 |
[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 339 |
| Placebo | 368 |
Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 201 |
| Placebo | 233 |
[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 162 |
| Placebo | 125 |
This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 0 |
"To compare the estimated blood loss in patients undergoing complex, reconstructive, spinal fusion surgeries receiving one of two dosing protocols for the anti-fibrinolytic, TXA.~Estimated blood loss was calculated by suction canister volume minus intraoperative irrigation fluid plus blood content in sponges as estimated by weight for all cases." (NCT02053363)
Timeframe: This outcome is measured during surgery, from exposure to wound closure, approximately 8 hours.
| Intervention | mL (Mean) |
|---|---|
| High Dose/Study Group | 2046 |
| Standard of Care/Control | 1596 |
To compare the rates of intraoperative complications and 90 day complications observed in the two groups. (NCT02053363)
Timeframe: Perioperative complications were defined as complications occurring within 90 days of surgery.
| Intervention | Participants (Count of Participants) |
|---|---|
| High Dose/Study Group | 2 |
| Standard of Care/Control | 3 |
To compare the mean volume (mL) of packed red blood cell (PRBC) transfusions given to the two groups. Volumes of RBC vary from bag to bag and real volumes will be recorded as provided by the blood bank. (NCT02053363)
Timeframe: Participants will be followed for the duration of their hospital stay measured from day of surgery to day of discharge from the hospital, approximately 7 days.
| Intervention | mL (Mean) |
|---|---|
| High Dose/Study Group | 1259 |
| Standard of Care/Control | 935 |
Blood loss following surgery was defined as the total amount of fluid collected from the drain in the wound site during the hospital stay. (NCT02063035)
Timeframe: From end of surgery on Day 1 to end of hospital stay up to approximately 5 days
| Intervention | mL (Median) |
|---|---|
| Tranexamic Acid | 534 |
| Placebo | 530 |
Blood loss was calculated from the difference between the level of hemoglobin at the preoperative appointment and the lowest level during the postoperative hospitalization period. Reported here is the change in hemoglobin level after surgery. A negative number indicates a reduction in hemoglobin level. (NCT02063035)
Timeframe: From preoperative appointment approximately one week before surgery to end of hospital stay up to approximately 5 days after surgery
| Intervention | grams per deciliter (g/dL) (Median) |
|---|---|
| Tranexamic Acid | -3.2 |
| Placebo | -4.6 |
The number of days the participants stayed in the hospital after surgery was recorded. (NCT02063035)
Timeframe: From end of surgery on Day 1 to end of hospital stay up to approximately 2 weeks
| Intervention | days (Median) |
|---|---|
| Tranexamic Acid | 5 |
| Placebo | 6 |
All units of blood transfused during the hospital stay after surgery were recorded. One red blood cell unit contains 300 to 360 mL of whole blood. (NCT02063035)
Timeframe: From end of surgery on Day 1 to end of hospital stay up to approximately 5 days
| Intervention | units of blood (Median) |
|---|---|
| Tranexamic Acid | 0 |
| Placebo | 0 |
Incidence of VTE (symptomatic of DVT or PE), infection (superficial, deep), hematoma, seroma, reoperation, and death, measured in person-years ( x cases per 100,000 person years) (NCT02257580)
Timeframe: an expected average of 1 week (post-surgery), Follow-up at 6 weeks
| Intervention | cases per 100,000 person years (Number) |
|---|---|
| E-Aminocaproic Acid (EACA) | 0 |
| Placebo | 0 |
Determined by estimated blood volume, calculated using difference in preoperative and postoperative hemoglobin and applied to the Nadler equation for estimating blood volume while adjusting for transfused hemoglobin to produce a single metric of calculated intraoperative blood loss. (NCT02257580)
Timeframe: Intraoperative (3-6 hours)
| Intervention | mL (Mean) |
|---|---|
| E-Aminocaproic Acid (EACA) | 535.7 |
| Placebo | 628.0 |
Number of participants requiring 1 unit of intraoperative cell saver transfusion. Patients either received or did not receive intraoperative cell saver transfusion. The maximum number of intraoperative units transfused in this study was 1 unit. The count of participants in the data table refers to the number of patients who received this transfusion. (NCT02257580)
Timeframe: Intraoperative, 1 day
| Intervention | Participants (Count of Participants) |
|---|---|
| E-Aminocaproic Acid (EACA) | 7 |
| Placebo | 7 |
postoperative day of discharge after surgery- day of intake. (NCT02257580)
Timeframe: Post-Surgery, an expected average of 1 week
| Intervention | days (Mean) |
|---|---|
| E-Aminocaproic Acid (EACA) | 5.5 |
| Placebo | 5.1 |
24 hour drain output (mL) (NCT02257580)
Timeframe: Post-Surgery, 24 hours
| Intervention | mL (Mean) |
|---|---|
| E-Aminocaproic Acid (EACA) | 72.5 |
| Placebo | 103.3 |
The number of participants that required 1 unit of blood transfused post-operatively. Patients received blood if necessary post operatively, and the maximum number of units a patient received was 1. The count of participants refers to the number of patients who received this transfusion unit. (NCT02257580)
Timeframe: Post-Surgery, an expected average of 1 week
| Intervention | Participants (Count of Participants) |
|---|---|
| E-Aminocaproic Acid (EACA) | 4 |
| Placebo | 3 |
Total additional blood products (fresh frozen plasma, cryoprecipitate, and platelets) transfused in the perioperative period measured in units. (NCT01728636)
Timeframe: 24 hours after skin incision
| Intervention | Units (Mean) |
|---|---|
| Tranexamic Acid | 1 |
| Placebo | 2 |
Estimated Intraoperative blood loss in milliliters (mLs) (NCT01728636)
Timeframe: Incision to skin closure (approximately 10 hours)
| Intervention | Milliliters (Mean) |
|---|---|
| Tranexamic Acid | 1550 |
| Placebo | 1600 |
Number of participants who experienced arterial or venous thromboembolism, neurologic complications (including stroke, seizure,and delirium), infections, and pulmonary renal or cardiac adverse outcomes (demand ischemia, myocardial infarction or new arrhythmia) before another operative procedure or hospital discharge. (NCT01728636)
Timeframe: Time of surgery to date of discharge from hospital (average 7 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 9 |
| Placebo | 9 |
Total operating room time from incision to closure of incision in minutes. (NCT01728636)
Timeframe: Minutes
| Intervention | Minutes (Median) |
|---|---|
| Tranexamic Acid | 602 |
| Placebo | 576 |
Total red blood cells transfused in the intraoperative period in (mL). Total RBC equal packed red blood cells and cell saver infusion. (NCT01728636)
Timeframe: Intraoperative period (approximately 12 hours)
| Intervention | milliliters (Median) |
|---|---|
| Tranexamic Acid | 1140 |
| Placebo | 1460 |
Total milligrams of intravenous tranexamic acid administered during the surgical procedure. (NCT01728636)
Timeframe: Intraoperative period
| Intervention | milligrams (Median) |
|---|---|
| Tranexamic Acid | 1408 |
| Placebo | 0 |
Estimated Blood Loss defined as Pre Op Hgb mins the Post Op Day two Hgb. (NCT01866943)
Timeframe: Pre Op, Post Op Day 2
| Intervention | Hemoglobin (grams/deciliter) (Mean) |
|---|---|
| Baseline Population | 2.93 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 2 week
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 65.76 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 6 week
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 81.77 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: Preoperative
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 58.34 |
Measurement of the thigh at the half way point between the prominence of the greater trochanter and the lateral epicondyle of the femur. No data recorded at 2 weeks or 6 weeks for this study population. (NCT01866943)
Timeframe: Pre Op
| Intervention | centimeters (Mean) |
|---|---|
| Baseline Population | 52.99 |
(NCT00958581)
Timeframe: 1 Week
| Intervention | ml (Mean) |
|---|---|
| Epsilon Aminocaproic Acid | 1775 |
| Normal Saline | 2116 |
| Tranexamic Acid | 1531 |
The number of breasts with clinically significant hematoma (collection of blood under the skin) requiring either conservative management or operative washout was determined. (NCT04947514)
Timeframe: Up to 30 days
| Intervention | breasts (Number) |
|---|---|
| Treatment Side (Right or Left) | 2 |
| Placebo Side (Right or Left) | 1 |
The number of participants requiring blood transfusion was based on the postoperative decline in hematocrit level (NCT04947514)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Side (Right or Left) | 0 |
| Placebo Side (Right or Left) | 0 |
Incidence of clinically significant deep vein thrombosis or pulmonary embolism detected on imaging (ultrasound or CT scan) (NCT04947514)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Side (Right or Left) | 0 |
| Placebo Side (Right or Left) | 0 |
"Functional outcomes measured by the 2011 Knee Society Score. The Functional Activities section consists of 4 sub-sections with a total score ranging from 0-100 points. The higher the numerical value the better the outcome. The sub-sections consist of: (1)Walking and Standing 0-30 points (2)Standard Activities 0-30 points (3)Advanced Activities 0-25 points (4)Discretionary Knee Activities 0-15 points." (NCT03952546)
Timeframe: 8 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Arm | 56.45 |
| Control Arm | 61.79 |
Postoperative day 1 estimated blood loss as calculated by the Gross' Formula (NCT03952546)
Timeframe: Postoperative day 1
| Intervention | milliliters (Mean) |
|---|---|
| Treatment Arm | 924 |
| Control Arm | 1062 |
Participants were assessed for any wound infection within 90 days of surgery. (NCT03952546)
Timeframe: 90 days postoperatively
| Intervention | Number of events (Number) |
|---|---|
| Saline-Coupled Bipolar Sealer | 1 |
| Unipolar Electrocautery | 3 |
Measured in Days (NCT03825939)
Timeframe: At Hospital Discharge
| Intervention | Days (Mean) |
|---|---|
| Intravenous Tranexamic Acid | 3 |
| Intravenous Placebo | 3 |
| Intravenous Tranexamic Acid Followed by Intravenous Placebo | 3 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Deep venous thrombosis" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Hematoma" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Infection" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Myocardial infarction" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 1 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Pulmonary Embolism" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
Total Blood Loss as calculated according to method as described by Good et al. Total Blood Loss (mL) = 1000 X Hb(loss)/Hb(initial) (NCT02043132)
Timeframe: Preoperative through Postoperative Days 1 and 2
| Intervention | Total Blood Loss (mL) (Mean) |
|---|---|
| Tranexamic Acid | 1122.4 |
| Normal Saline | 1472 |
Total Drain Output as measured postoperatively 0-48 hours (NCT02043132)
Timeframe: 0-48 hours postoperatively
| Intervention | mL (Mean) |
|---|---|
| Tranexamic Acid | 221 |
| Normal Saline | 372 |
Total hemoglobin loss estimated using the formula for total blood volume described by Nadler et al Hb(loss) = blood volume (L) x [Hb(initial)(g/L) - Hb(final)(g/L)] + Hb(transfused) (NCT02043132)
Timeframe: Preoperative through Postoperative Days 1 and 2
| Intervention | g (Mean) |
|---|---|
| Tranexamic Acid | 154.6 |
| Normal Saline | 200.1 |
44 reviews available for aminocaproic acid and Blood Loss, Surgical
| Article | Year |
|---|---|
The Efficacy and Safety of Epsilon-Aminocaproic Acid for Perioperative Blood Management in Spinal Fusion Surgery: A Systematic Review and Meta-Analysis.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Humans; | 2021 |
Antifibrinolytic Drugs for the Prevention of Bleeding in Pediatric Cardiac Surgery on Cardiopulmonary Bypass: A Systematic Review and Meta-analysis.
Topics: Aminocaproic Acid; Anaphylaxis; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Su | 2022 |
Blood Loss and Transfusion in a Pediatric Scoliosis Surgery Cohort in the Antifibrinolytic Era.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Humans; Retrosp | 2022 |
Tranexamic Acid versus Epsilon-Aminocaproic Acid in Total Knee Arthroplasty: A Meta-Analysis.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; H | 2021 |
[Hemostatic efficacy of tranexamic acid and ε-aminocaproic acid in hip and knee arthroplasty:a Meta-analysis].
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2022 |
The optimal regimen, efficacy and safety of tranexamic acid and aminocaproic acid to reduce bleeding for patients after total hip arthroplasty: A systematic review and Bayesian network meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
The optimal regimen, efficacy and safety of tranexamic acid and aminocaproic acid to reduce bleeding for patients after total hip arthroplasty: A systematic review and Bayesian network meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
The optimal regimen, efficacy and safety of tranexamic acid and aminocaproic acid to reduce bleeding for patients after total hip arthroplasty: A systematic review and Bayesian network meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
The optimal regimen, efficacy and safety of tranexamic acid and aminocaproic acid to reduce bleeding for patients after total hip arthroplasty: A systematic review and Bayesian network meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
The Optimal Dose, Efficacy and Safety of Tranexamic Acid and Epsilon-Aminocaproic Acid to Reduce Bleeding in TKA: A Systematic Review and Bayesian Network Meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
Comparison of efficacy between tranexamic acid and epsilon-aminocaproic acid for total knee arthroplasty: A meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
Efficacy and Safety of Antifibrinolytic Drugs in Pediatric Surgery: A Systematic Review.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Humans; Pharmaceutical Prep | 2021 |
Preventing perioperative bleeding in patients with inherited bleeding disorders.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Hemophilia A; Humans; Postoperativ | 2017 |
The Safety and Efficacy of Lysine Analogues in Cancer Patients: A Systematic Review and Meta-Analysis.
Topics: Adult; Aminocaproic Acid; Blood Loss, Surgical; Blood Transfusion; Erythrocyte Transfusion; Humans; | 2017 |
The effectiveness and safety of aminocaproic acid for reducing blood loss in total knee and hip arthroplasty: A meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2018 |
Tranexamic acid versus aminocaproic acid for blood management after total knee and total hip arthroplasty: A systematic review and meta-analysis.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2018 |
Use of antifibrinolytics in pediatric cardiac surgery: Where are we now?
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2019 |
The Role of Antifibrinolytics in Reducing Blood Loss During Craniofacial or Orthognathic Surgical Procedures: A Meta-Analysis.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Denmark; Humans; Ort | 2019 |
Efficacy of aminocaproic acid in the control of bleeding after total knee and hip arthroplasty: A systematic review and meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2019 |
The Efficacy and Safety of Epsilon-Aminocaproic Acid for Blood Loss and Transfusions in Spinal Deformity Surgery: A Meta-Analysis.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Neurosu | 2019 |
Epsilon-aminocaproic acid versus tranexamic acid in total knee arthroplasty: a meta-analysis study.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; B | 2019 |
Antifibrinolytic drugs for acute traumatic injury.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Hemo | 2012 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
[Hemostasis and antifibrinolytic therapy in major pediatric surgery].
Topics: Adolescent; Age Factors; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical | 2013 |
The effects of lysine analogs during pelvic surgery: a systematic review and meta-analysis.
Topics: Aminocaproic Acid; Blood Loss, Surgical; Blood Transfusion; Gynecologic Surgical Procedures; Hemorrh | 2014 |
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Factor VIIa; Hemophilia A; Hemophi | 2015 |
Antifibrinolytic drugs for acute traumatic injury.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Hemo | 2015 |
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Factor IX; Factor VIII; Hemophilia | 2015 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The use of antifibrinolytic agents in spine surgery. A meta-analysis.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Huma | 2008 |
The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Coronary Artery | 2009 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Antifibrinolytics in major orthopaedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Huma | 2010 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Erythrocyte Tran | 2011 |
A systematic review of the use of antifibrinolytic agents in pediatric surgery and implications for craniofacial use.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Card | 2012 |
Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2012 |
Antifibrinolytics.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Hemo | 2003 |
Strategies for minimizing blood loss in orthopedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Blood Loss, Surg | 2004 |
Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Bayes Theorem; Blood Loss, Surgical; Blood Tr | 2005 |
Antifibrinolytics in liver transplantation.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Humans; Liver Transplan | 2006 |
Current antifibrinolytic therapy for coronary artery revascularization.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Coro | 2008 |
Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding.
Topics: Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Coronary Artery Byp | 1994 |
Natural and synthetic antifibrinolytics in adult cardiac surgery: efficacy, effectiveness and efficiency.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusio | 1994 |
Blood-sparing drugs: aprotinin, tranexamic acid, and epsilon-aminocaproic acid.
Topics: Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Graft Occlusion, Va | 1995 |
Antifibrinolytic therapy in cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Tests; Blood Loss, Surgical | 1995 |
Clinical use of synthetic antifibrinolytic agents during liver transplantation.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Loss, Surgical; Clini | 1993 |
Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators.
Topics: Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; | 1997 |
Current status of non-transfusional haemostatic agents.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Blood Loss, Surg | 1999 |
40 trials available for aminocaproic acid and Blood Loss, Surgical
| Article | Year |
|---|---|
Local administration of epsilon-aminocaproic acid reduces post-operative blood loss from surgery for closed, Sanders III-IV calcaneal fractures.
Topics: Aminocaproic Acid; Blood Loss, Surgical; Calcaneus; Fracture Fixation, Internal; Fractures, Bone; Hu | 2022 |
Tranexamic acid or epsilon-aminocaproic acid in total joint arthroplasty? A randomized controlled trial.
Topics: Administration, Intravenous; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replace | 2019 |
Effects of aminocaproic acid on perioperative hidden blood loss in elderly patients with femoral intertrochanteric fracture treated with proximal femoral nail anti-rotation.
Topics: Aged; Aminocaproic Acid; Blood Loss, Surgical; Bone Nails; Case-Control Studies; Female; Femur; Hip | 2019 |
Safety and efficacy of epsilon aminocaproic acid (EACA) as an antihemorrhagic drug in bilateral one stage total knee arthroplasty: A double-blind randomized controlled trial.
Topics: Administration, Intravenous; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replace | 2020 |
Effect of Intravenous Aminocaproid Acid on Blood Loss and Transfusion Requirements After Bilateral Varus Rotational Osteotomy: A Double-blind, Placebo-controlled Randomized Trial.
Topics: Administration, Intravenous; Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Sur | 2020 |
Blood Conservation Using Tranexamic Acid Is Not Superior to Epsilon-Aminocaproic Acid After Total Knee Arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacemen | 2017 |
A randomized trial of the topical effect of antifibrinolytic epsilon aminocaproic Acid on coronary artery bypass surgery without cardiopulmonary bypass.
Topics: Administration, Topical; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Car | 2014 |
Does Amicar affect blood loss in patients with adolescent idiopathic scoliosis treated with pedicle screws and Ponte osteotomies?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Bone Screws; Female; Humans | 2013 |
Comparison of epsilon aminocaproic acid and tranexamic Acid in thoracic aortic surgery: clinical efficacy and safety.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aorta, Thoracic; Blood Loss, Surgical; Blood Tran | 2013 |
The relative efficacy of antifibrinolytics in adolescent idiopathic scoliosis: a prospective randomized trial.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Dou | 2014 |
Antifibrinolytics reduce blood loss in adult spinal deformity surgery: a prospective, randomized controlled trial.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Vo | 2015 |
The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized, double-blind, placebo-controlled, noninferiority trial.
Topics: Aged; Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Coronary Artery Bypass; Double-Blind Metho | 2009 |
Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion, Au | 2009 |
Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion, Au | 2009 |
Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion, Au | 2009 |
Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion, Au | 2009 |
A prospective, randomized, double-blinded single-site control study comparing blood loss prevention of tranexamic acid (TXA) to epsilon aminocaproic acid (EACA) for corrective spinal surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, | 2010 |
Blood conservation strategies for reducing peri-operative blood loss in open heart surgery.
Topics: Adult; Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Female; Huma | 2011 |
Population pharmacokinetics of epsilon-aminocaproic acid in infants undergoing craniofacial reconstruction surgery.
Topics: Age Factors; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Bo | 2013 |
Antifibrinolytic therapy and perioperative blood loss in cancer patients undergoing major orthopedic surgery.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Cell Count; Blood Loss, Surgical; | 2003 |
Epsilon-aminocaproic acid in coronary artery bypass graft surgery: preincision or postheparin?
Topics: Aged; Aminocaproic Acid; Blood Loss, Surgical; Chest Tubes; Coronary Artery Bypass; Double-Blind Met | 2003 |
The effect of amicar on perioperative blood loss in idiopathic scoliosis: the results of a prospective, randomized double-blind study.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Dou | 2004 |
The role of amicar in decreasing perioperative blood loss in idiopathic scoliosis.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Double-Blind Me | 2005 |
The role of amicar in decreasing perioperative blood loss in idiopathic scoliosis.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Double-Blind Me | 2005 |
The role of amicar in decreasing perioperative blood loss in idiopathic scoliosis.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Double-Blind Me | 2005 |
The role of amicar in decreasing perioperative blood loss in idiopathic scoliosis.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Double-Blind Me | 2005 |
A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Co | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2006 |
Evaluation of Epsilon amino-caproic acid (EACA) and autologous blood as blood conservation strategies in patients undergoing cardiac surgery.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion, Autologo | 2006 |
Differential effects of epsilon-aminocaproic acid and aprotinin on matrix metalloproteinase release in patients following cardiopulmonary bypass.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiopulmonary Bypass; | 2008 |
Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Tests; Blood L | 1995 |
The intraoperative use of Amicar to reduce bleeding associated with open heart surgery.
Topics: Aged; Aminocaproic Acid; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Chest | 1995 |
Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. A randomized, prospective, double-blind study.
Topics: Aged; Aminocaproic Acid; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; Double-Bli | 1994 |
Decreased postoperative drainage with addition of epsilon-aminocaproic acid before cardiopulmonary bypass.
Topics: Aminocaproic Acid; Blood Coagulation; Blood Component Transfusion; Blood Loss, Surgical; Blood Trans | 1994 |
Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid.
Topics: Aminocaproic Acid; Aprotinin; Blood Coagulation; Blood Loss, Surgical; Blood Transfusion; Cardiopulm | 1996 |
Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Su | 1997 |
Prophylactic tranexamic acid and epsilon-aminocaproic acid for primary myocardial revascularization.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Coronary Artery | 1998 |
Hemostatic effects of aprotinin, tranexamic acid and epsilon-aminocaproic acid in primary cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Card | 1999 |
Epsilon aminocaproic acid in paediatric cardiac surgery to reduce postoperative blood loss.
Topics: Aminocaproic Acid; Blood Loss, Surgical; Child; Coronary Artery Bypass; Heart Defects, Congenital; H | 2000 |
Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Coagulation; Blood Component Transfus | 2000 |
Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Tests; Blood Lo | 2000 |
Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiopulmonary Bypass; | 2001 |
The efficacy of antifibrinolytics in the reduction of blood loss during complex adult reconstructive spine surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Coagulation; Blood Loss, Surgical; Bloo | 2001 |
The effect of epsilon aminocaproic acid on blood loss in patients who undergo primary total hip replacement: a pilot study.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2002 |
[Comparison of the effects of epsilon-aminocaproic acid and aprotinin on intra- and postoperative bleeding in heart surgery].
Topics: Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Coronary Artery Bypass; Female; Heart Septal Def | 1992 |
The effect of warm heart surgery on postoperative bleeding.
Topics: Aminocaproic Acid; Analysis of Variance; Blood Loss, Surgical; Blood Transfusion; Chi-Square Distrib | 1992 |
62 other studies available for aminocaproic acid and Blood Loss, Surgical
| Article | Year |
|---|---|
Comment on article by Zhong et al.: Local administration of epsilon-aminocaproic acid reduces post-operative blood loss from surgery for closed, Sanders III-IV calcaneal fractures.
Topics: Aminocaproic Acid; Ankle Injuries; Blood Loss, Surgical; Calcaneus; Humans | 2022 |
Effectiveness and Safety of E-aminocaproic Acid in Overall and Less-Invasive Cardiac Surgeries.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures | 2022 |
Comparison of trauma-dosed tranexamic acid versus aminocaproic acid in cardiac surgery in the setting of drug shortage.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Human | 2022 |
Safety of antifibrinolytics in 6583 pediatric patients having craniosynostosis surgery: A decade of data reported from the multicenter Pediatric Craniofacial Collaborative Group.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Craniosynostoses; Humans; I | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study.
Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2022 |
Combination of Intravenous and Intra-Articular Application of Tranexamic Acid and Epsilon-Aminocaproic Acid in Primary Total Knee Arthroplasty: A Prospective Randomized Controlled Trial.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
Epsilon aminocaproic acid is associated with acute kidney injury after life-threatening hemorrhage in children.
Topics: Acute Kidney Injury; Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; C | 2023 |
Antifibrinolytic agents and seizure risk in neonates undergoing cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Human | 2023 |
Efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Hip Fractures; Humans; Posto | 2023 |
In response: Approaching risk assessment with caution: Epsilon aminocaproic acid and acute kidney injury in the secondary analysis.
Topics: Acute Kidney Injury; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Risk | 2023 |
Antifibrinolytic Therapy in Surgery for Adolescent Idiopathic Scoliosis Does the Level 1 Evidence Translate to Practice?
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Cohort Studies; | 2018 |
Dose Comparison of Epsilon-Aminocaproic Acid to Reduce Blood Loss in Infants Undergoing Cranial Vault Reconstruction Surgery: A Retrospective Pilot Study.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Craniosynostoses; Humans; Infant; | 2020 |
Individualized Perioperative Antifibrinolytic Therapy: The Next Goal in Cardiac Surgery?
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardi | 2021 |
Lysine analogue use during cancer surgery: a survey from a Canadian tertiary care centre.
Topics: Aminocaproic Acid; Blood Loss, Surgical; Humans; Lysine; Neoplasms; Ontario; Surveys and Questionnai | 2020 |
ε-Aminocaproic acid versus tranexamic acid in children undergoing complex cranial vault reconstruction for repair of craniosynostosis.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Craniosynostoses; Humans; R | 2021 |
Epsilon Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Hip and Total Knee Arthroplasty.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2018 |
Topically Applied Epsilon-Aminocaproic Acid Reduces Blood Loss and Length of Hospital Stay After Total Knee Arthroplasty.
Topics: Administration, Topical; Aged; Aminocaproic Acid; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2017 |
Bipolar Sealer Devices Used in Posterior Spinal Fusion for Neuromuscular Scoliosis Reduce Blood Loss and Transfusion Requirements.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cas | 2018 |
Pharmacologic Hemostatic Agents in Total Joint Arthroplasty-A Cost-Effectiveness Analysis.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2018 |
There seems to be no benefit from using ε-aminocaproic acid in addition to routine postextraction advice in patients receiving anticoagulation therapy.
Topics: Aminocaproic Acid; Anticoagulants; Blood Loss, Surgical; Humans | 2018 |
Unexpected higher blood loss associated with higher dose ε-aminocaproic acid in pediatric scoliosis surgery.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Dose-Response Relation | 2019 |
Disseminated intravascular coagulation during liver transplantation unleashed by protamine.
Topics: Aged; Aminocaproic Acid; Blood Loss, Surgical; Carcinoma, Hepatocellular; Disseminated Intravascular | 2019 |
Comparison of different dosage regimes of epsilon aminocaproic acid on blood loss in children undergoing craniosynostosis surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Craniosynostoses; Erythrocyte Tran | 2019 |
Minimizing transfusions in primary cranial vault remodeling: the role of aminocaproic acid.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Arterial Pressure; Blood Loss, Surgical; Blood Transfusi | 2014 |
Increased recombinant activated factor VII use and need for surgical reexploration following a switch from aprotinin to epsilon-aminocaproic acid in infant cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Card | 2014 |
The effects of Amicar and TXA on lumbar spine fusion in an animal model.
Topics: Aminocaproic Acid; Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Calcification, Physiologi | 2014 |
Efficacy and safety of tranexamic acid versus ϵ-aminocaproic acid in cardiovascular surgery.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiopul | 2014 |
Aminocaproic acid administration is associated with reduced perioperative blood loss and transfusion in pediatric craniofacial surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child, Preschoo | 2016 |
Association of Epsilon-Aminocaproic Acid With Blood Loss and Risk of Transfusion After Periacetabular Osteotomy: A Retrospective Cohort Study.
Topics: Acetabulum; Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blo | 2016 |
Peri-operative blood-loss after total hip arthroplasty can be significantly reduced with topical application of epsilon-aminocaproic acid.
Topics: Administration, Topical; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement | 2016 |
Comparison of ε-Aminocaproic Acid and Tranexamic Acid in Reducing Postoperative Transfusions in Total Hip Arthroplasty.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2016 |
Effect of Antifibrinolytic Therapy on Complications, Thromboembolic Events, Blood Product Utilization, and Fusion in Adult Spinal Deformity Surgery.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; | 2016 |
Blood loss and transfusion requirements with epsilon-aminocaproic acid use during cranial vault reconstruction surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Bone Transplant | 2017 |
Safety of antifibrinolytics in cranial vault reconstructive surgery: a report from the pediatric craniofacial collaborative group.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Child, Preschool; Cooperati | 2017 |
The role of Amicar in same-day anterior and posterior spinal fusion for idiopathic scoliosis.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Chi | 2008 |
Role of Amicar in surgery for neuromuscular scoliosis.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cas | 2008 |
ε-Aminocaproic acid and clinical value in cardiac anesthesia.
Topics: Algorithms; Aminocaproic Acid; Anesthesia; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; | 2011 |
The post-BART anti-fibrinolytic dilemma?
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2011 |
Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid.
Topics: Aged; Aminocaproic Acid; Anesthesia; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical | 2011 |
Comparison of blood-sparing efficacy of ε-aminocaproic acid and tranexamic acid in newborns undergoing cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgica | 2011 |
Are antifibrinolytics helpful in decreasing blood loss and transfusions during spinal fusion surgery in children with cerebral palsy scoliosis?
Topics: Adolescent; Aminocaproic Acid; Analysis of Variance; Antifibrinolytic Agents; Blood Loss, Surgical; | 2012 |
Acute hyperkalemia as a complication of intravenous therapy with epsilon-aminocaproic acid.
Topics: Acute Disease; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Los | 2011 |
Replacement of aprotinin by ε-aminocaproic acid in infants undergoing cardiac surgery: consequences for blood loss and outcome.
Topics: Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; | 2013 |
Epsilon-amino caproic acid additive decreases fibrin bandage performance in a swine arterial bleeding model.
Topics: Aminocaproic Acid; Animals; Arteries; Blood Coagulation; Blood Coagulation Tests; Blood Loss, Surgic | 2002 |
[SATISFACTORY RESULTS OF HEMOCAPROL THERAPY IN CERTAIN HEMORRHAGIC OPERATIONS].
Topics: Aminocaproates; Aminocaproic Acid; Blood Loss, Surgical; Hemorrhage; Hemostasis; Surgical Procedures | 1964 |
Identifying patients at risk of intraoperative and postoperative transfusion in isolated CABG: toward selective conservation strategies.
Topics: Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Anticoagulants; Blood Component Transfusion; Bloo | 2004 |
Antifibrinolytic use and bleeding during surgery on the descending thoracic aorta: a multivariate analysis.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aortic Aneurysm, Thoracic; Blood Loss, Surgical; D | 2005 |
[Hemostatic drugs in a patient with antiphospholipid syndrome and clinically significant perioperative bleeding].
Topics: Adult; Aminocaproic Acid; Antiphospholipid Syndrome; Aprotinin; Blood Coagulation Tests; Blood Loss, | 2006 |
[The "Seville" Consensus Document on Alternatives to Allogenic Blood Transfusion. Sociedades españolas de Anestesiología (SEDAR), Medicina Intensiva (SEMICYUC), Hematología y Hemoterapia (AEHH), Transfusión sanguínea (SETS) Trombosis y Hemostasia (SETH)].
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Substitutes; Bloo | 2006 |
Pro: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery.
Topics: Aminocaproic Acid; Animals; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Drug Hyper | 2006 |
Recombinant activated factor VII and epsilon aminocaproic acid treatment of a patient with Glanzmann's thrombasthenia for nasal polipectomy.
Topics: Adult; Aminocaproic Acid; Anesthesia, General; Antifibrinolytic Agents; Blood Loss, Surgical; Drug T | 2007 |
[Effectiveness of tranexamic acid in routine performance of total knee replacement surgery].
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee | 2008 |
Blood loss and transfusion requirements in cystic fibrosis patients undergoing heart-lung or lung transplantation.
Topics: Adult; Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Child; Cystic Fibrosis | 1995 |
Prophylactic epsilon-aminocaproic acid (EACA) administration minimizes blood replacement therapy during cardiac surgery.
Topics: Aminocaproic Acid; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Humans; Ret | 1995 |
Drugs for surgical blood loss.
Topics: Aminocaproic Acid; Blood Loss, Surgical; Humans; Serine Proteinase Inhibitors; Tranexamic Acid | 1993 |
Prevention of postbypass bleeding with tranexamic acid and epsilon-aminocaproic acid.
Topics: Aminocaproic Acid; Blood Loss, Surgical; Blood Transfusion; Cardiopulmonary Bypass; Coronary Artery | 1993 |
Cost/benefit analysis of pharmacologic hemostasis.
Topics: Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; Cost- | 1996 |
Hemophilia and EACA.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Dental Care for Chronically Ill; H | 1996 |
Acute hyperkalemia associated with intravenous epsilon-aminocaproic acid therapy.
Topics: Acute Disease; Aged; Aminocaproic Acid; Arginine; Blood Loss, Surgical; Coronary Artery Bypass; Huma | 1999 |
Efficacy of epsilon-aminocaproic acid in children undergoing cardiac surgery.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Blood Coagulation; Blood Loss, Surgic | 1999 |
The Effect of epsilon-aminocaproic acid on perioperative blood loss in patients with idiopathic scoliosis undergoing posterior spinal fusion: a preliminary prospective study.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion, Aut | 2001 |
Does prophylactic epsilon-aminocaproic acid improve blood loss and coagulation in liver transplantation?
Topics: Aminocaproic Acid; Blood Coagulation; Blood Loss, Surgical; Humans; Liver Transplantation; Retrospec | 1991 |